1. 脑胶质瘤组织长链非编码RNA FTX、RHPN1-AS1表达与预后的关系.
- Author
-
陈金辉, 罗斌, 姚黎辉, 张策, and 袁立
- Subjects
- *
RNA , *KARNOFSKY Performance Status , *PROGRESSION-free survival , *SURVIVAL analysis (Biometry) , *OVERALL survival , *BRAIN tumors - Abstract
Objective: To investigate the relationship between long non-coding ribonucleic acid (LncRNA) FTX, RHPN1-AS1 expression and prognosis in glioma tissue. Methods: A total of 105 cases of glioma patients in our hospital were selected from the surgically resected cancerous tissues and adjacent cancerous tissues (3~5cm from the tumor edge). Real-time quantitative reverse transcription PCR (qRT-PCR) was used to detect the expression of LncRNA FTX and RHPN1-AS1 in tissues. The relationship between LncRNA FTX and RHPN1-AS1 expression and clinicopathological features of glioma were analyzed. The 5-year progression-free survival time and overall survival time of glioma patients with different LncRNA FTX and RHPN1-AS1 expression were plotted by K-M method. Factors influencing poor prognosis in glioma patients were analyzed by Cox regression. Results: LncRNA FTX, RHPN1-AS1 expression levels in glioma tissues was higher than those in adjacent tissues(P<0.05). LncRNA FTX, RHPN1-AS1 expression was correlated with Karnofsky Performance Status (KPS) score and World Health Organization (WHO) classification in glioma patients (P<0.05). Progression-free survival time and overall survival time were shorter in the LncRNA FTX, RHPN1-AS1 high expression group than those in the low expression group (P<0.05). KPS score (HR=2.621, 95%CI: 1.284~5.348), WHO classification (HR=2.264, 95%CI: 1.152~4.449), LncRNA FTX (HR=1.997, 95%CI: 1.017~3.922), and LncRNA RHPN1-AS1 (HR=2.431, 95%CI: 1.257~4.701) were influence factors for poor prognosis in glioma patients (P<0.05). Conclusions: The expression levels of LncRNA FTX and RHPM1-AS1 in glioma tissues were increased, and both of them, KPS score and WHO grade were factors influencing the poor prognosis of patients, which could be used to evaluate the prognosis of glioma patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF